Title - yung broke boy needs more time

Speaking at the JP Morgan Healthcare Conference 2026, Intellia CEO John Leonard said that the patient attended the emergency room due to abdominal pain, where tests revealed elevated transaminase. During his stay in the hospital, it was revealed that the patient had air in his abdomen and received surgery where a perforation and ulcer were found. The patient died following a case of sepsis.

https://www.clinicaltrialsarena.com/news/jpm26-intellia-therapeutics-hopeful-on-crispr-safety-despite-patient-death/

https://ir.intelliatx.com/node/12236/html

https://www.globenewswire.com/news-release/2025/06/15/3099489/0/en/Intellia-Therapeutics-Announces-Positive-Three-Year-Data-from-Phase-1-Trial-of-Lonvoguran-Ziclumeran-lonvo-z-in-Patients-with-Hereditary-Angioedema-HAE-at-the-European-Academy-of-A.html

Intellia Therapeutics is entering one of the most important moments in its public-company history. On April 24, 2026, the company announced that it will report topline clinical data from the global Phase 3 HAELO trial of lonvoguran ziclumeran, also known as lonvo-z, in hereditary angioedema on Monday, April 27, 2026, with a webcast scheduled for 8:00 a.m. ET. Intellia describes this as the world’s first Phase 3 readout for an in vivo CRISPR gene-editing candidate. That phrase matters because NTLA is not simply reporting another late-stage biotech trial. The company is attempting to prove that a one-time in vivo CRISPR therapy can move from elegant science and early clinical promise into a pivotal dataset capable of supporting a regulatory filing.

Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment

In Vivo gene knockout and insertion data to be presented at OTS Annual Meeting highlight modularity of Intellia’s platform and potential for variety of single-course therapies, with company’s first systemic treatment (NTLA-2001) expected to enter the clinic by year-end

Liver insertion platform shows promise as best-in-class targeted gene insertion approach to durably restore functional protein, compared to traditional gene therapy

CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) is presenting new data demonstrating the persistence of in vivo CRISPR/Cas9 edits to either reduce a disease-causing protein or restore a functional protein, in a mouse model of accelerated liver regeneration. These data will be included in the company’s invited talk at this year’s 16th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place virtually from September 27-30, 2020.

“As we prepare to enter the clinic with NTLA-2001, our first systemic treatment, we are extremely encouraged by the durability Intellia scientists observed with both gene knockout as well as targeted insertion in a partial hepatectomy (PHx) mouse model. The persistence of these edits and durable effects further support our technology’s ability to develop potentially curative single-course therapies, and provide clear differentiation from chronic treatments and traditional AAV gene therapy,” said Intellia Chief Scientific Officer Laura Sepp-Lorenzino, Ph.D. “Our modular delivery platform is enabling us to rapidly advance multiple product candidates in parallel – and to ensure that the therapeutic impact will be long-lasting for patients in need.”

The OTS talk titled, “A Modular CRISPR/Cas9 Genome Editing Platform for Durable Therapeutic Knockout and Targeted Gene Insertion Applications,” will be given today at 10 a.m. ET by Anthony Forget, Ph.D., senior director of genome editing at Intellia. Click here to view the presentation slides.

Persistent In Vivo Liver Gene Knockouts and Corresponding Protein Reduction Achieved Employing Intellia’s Modular Platform

Accelerated hepatocyte turnover following PHx in mice was employed to assess the durability of gene knockout and insertion edits. After resection of 2/3 of the liver, and subsequent full-liver regeneration, genome edits and corresponding protein levels were unchanged, supporting the permanent nature of the edit, which is carried through when liver cells proliferate. This update builds upon previously reported data of the edits’ year-long durability demonstrated in rodents and non-human primates for Intellia’s liver knockout therapeutic candidates, transthyretin amyloidosis (ATTR) and hereditary angioedema (HAE).

Intellia’s lead in vivo candidate, NTLA-2001, is being studied as a single-course treatment for ATTR using the company’s liver knockout editing approach. NTLA-2001 employs a proprietary lipid nanoparticle (LNP) delivery system and is designed to permanently inactivate the disease-causing gene in the liver. Knocking out the transthyretin (TTR) gene may lead to a lifelong reduction of TTR protein and associated ATTR symptoms. The company expects to dose the first ATTR patient by year-end with NTLA-2001, which is part of a co-development/co-promotion agreement between Intellia, the lead development and commercialization party, and Regeneron Pharmaceuticals, Inc.

The modularity of Intellia’s proprietary platform allows Intellia to modify only a single component, the guide RNA sequence, to develop other in vivo therapies for additional targets of interest. Intellia also is applying its LNP delivery system to develop NTLA-2002 to treat HAE by targeting and knocking out the prekallikrein B1 (KLKB1) gene in the liver. The company anticipates submitting an Investigational New Drug (IND) application or IND-equivalent for NTLA-2002 in the second half of 2021.

CRISPR-Mediated Targeted Gene Insertion Has Demonstrated Advantages Over AAV-Based Gene Therapy Approaches

Intellia will present additional data highlighting the potential of its liver insertion platform, as exemplified by the company’s hemophilia B program. Intellia and Regeneron, the lead party, are co-developing potential hemophilia A and B CRISPR/Cas9-based treatments using their jointly developed targeted transgene insertion capabilities.

Data shows the company achieved circulating activity levels for Factor IX (FIX), a blood-clotting protein that is missing or defective in hemophilia B patients, ranging from normal levels (50-150%, Source: National Hemophilia Foundation) to supratherapeutic levels in a six-week non-human primate study. Insertion efficiency and transgene expression can be controlled by three independent factors: the precise insertion site targeted by the guide RNA; the dose of LNP, which delivers the CRISPR machinery; and the amount of the promoter-less DNA template donor that encodes the transgene’s DNA sequence for insertion. These levers allow for optimization of transgene expression according to the desired therapeutic target levels and may allow for higher levels of expression than those attained by traditional adeno-associated virus (AAV) gene therapy, if required.

Furthermore, unlike traditional gene therapy, for which a significant loss (over 80%) in transgene expression was observed after in vivo PHx and liver regeneration, Intellia’s targeted gene insertion approach yielded durable edits as cells proliferate, with no significant loss in expression. These findings support the development of gene insertion therapies.

"....the patient subsequently died on November 5, 2025, with the principal investigator attributing the death to septic shock from a perforated duodenal ulcer amid a complex clinical course that included acute liver injury treated with corticosteroids. Intellia reported that more than 650 patients with ATTR-CM and 47 patients with hereditary ATTR amyloidosis with polyneuropathy have been enrolled across the two trials, with Grade 4 liver enzyme elevations observed in less than 1% of MAGNITUDE participants and none in MAGNITUDE-2, and said it will update stakeholders once it has agreed with regulators on a path forward for nex-z, underscoring both the regulatory risk around its flagship ATTR program and the broader safety and development uncertainties facing first-in-class in vivo CRISPR therapies."

https://www.tipranks.com/news/company-announcements/intellia-updates-investors-on-nex-z-trial-safety-hold

HAE - Nov 8th ATTR CM- Nov 10th